Universe Pharmaceuticals (UPC) Receivables (2020 - 2025)

Universe Pharmaceuticals (UPC) has 6 years of Receivables data on file, last reported at $15.3 billion in Q3 2025.

• For the quarter ending Q3 2025, Receivables fell 7.16% year-over-year to $15.3 billion; the trailing twelve-month figure through Sep 2025 stood at $15.3 billion (down 7.16% YoY), and the FY2025 full-year result was $9.7 billion, down 41.05% from the prior year.
• Receivables retreated to $15.3 billion in Q3 2025, from $16.5 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $16.5 billion in Q3 2024 to a low of $12.9 million in Q3 2023.
• A 5-year average of $4.0 billion and a median of $16.9 million in 2021 frame the typical range for Receivables.
• Across the five-year window, Receivables decreased 19.03% in 2023 and jumped 127214.19% in 2024, its largest moves.
• Tracing UPC's Receivables over 5 years: stood at $16.3 million in 2021, then decreased by 1.73% to $16.0 million in 2022, then declined by 19.03% to $12.9 million in 2023, then jumped by 127214.19% to $16.5 billion in 2024, then retreated by 7.16% to $15.3 billion in 2025.
• Business Quant data shows UPC's Receivables at $15.3 billion in Q3 2025, $16.5 billion in Q3 2024, and $14.4 million in Q1 2024.